<PAGE> 1
Filed by Coulter Pharmaceutical, Inc.
Pursuant to Rule 425 Under the
Securities Act of 1933
And Deemed Filed Pursuant to Rule
14a-12 Under the Securities
Exchange Act of 1934
Subject Company: Coulter
Pharmaceutical Inc. (Commission
File No. 0-21905)
SLIDES SHOWN IN ROADSHOW PRESENTATIONS
[Corixa Logo]
[Corixa Logo] The Immunotherapy Powerhouse
FORWARD LOOKING STATEMENTS
Except for the historical information presented, certain matters discussed in
this presentation are forward-looking statements. Forward-looking statements are
based on the opinions and estimates of management at the time the statements are
made. They are subject to certain risks and uncertainties that could cause
actual results to differ materially from any future results, performance or
achievements expressed or implied by such statements. Such risks and
uncertainties include risks associated with product discovery and development as
well as risks detailed from time to time in the companies' public disclosure
filings with the U.S. Securities and Exchange Commission (SEC), including its
Quarterly Reports on Form 10-Q, copies of which are available from the
companies' investor relations department. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the
date of this release.
[Corixa Logo]
TERMS OF TRANSACTION
- One of the largest biotech/biotech mergers in history
- Exchange ratio of 1.003 shares of Corixa for every 1.000 share of Coulter
- At the close of the transaction company ownership will be as follows:
- 56% held by Corixa shareholders
- 44% held by Coulter shareholders
[Corixa Logo]
TRANSACTION TIMING
- S-4 Registration Statement Filing
- Approximately 3 weeks
- SEC Response and Reply
- Proxy Mailing
- As soon as S-4 declared effective
- Shareholders' Meetings
- Mid-December
- Closing
- Immediately after shareholders' meetings
- Approximate Cash Position at Closing
- In excess of $170MM
[Corixa Logo]
ABOUT CORIXA SEATTLE corporate headquarters antigen discovery and validation
SOUTH SAN FRANCISCO Ab therapeutics, targeted oncology and autoimmune disease
therapeutics MONTANA GMP manufacturing adjuvants
[Corixa Logo]
INVESTMENT HIGHLIGHTS
- Combination of two leading biotechnology companies to create immunotherapy
leader
- Technology and product rich
- Industrialized antigen discovery machine
- Antibody therapeutics
- Targeted oncologics
- "Powered by Corixa" approach to component technologies
- Diverse pipeline, with multiple late stage product opportunities
- Strong partners - targeted sales force
[Corixa Logo]
<PAGE> 2
COMBINATION STRATEGY
- A large diverse pipeline
- Now 16 clinical programs, 22 pre-clinical programs
- Antigen to product capability
- Antigen discovery platform
- Therapeutic antibodies -- cytotoxic and radionuclide linkage
- Delivery and adjuvant technology for vaccines
- Retain greater share of product revenue
- Selectively market products using targeted sales force
- Partner regionally, partner later
- Create a critical mass of technologies, products and capabilities that
cannot be ignored
- Build targeted salesforce for niche products
- Lead product, Bexxar, significant near term revenue potential
- Key asset for certain products within pipeline
- Acquire or in-license related products/technologies
- Includes acting as investor in exchange for Mabs, antigens, delivery
technologies; most diseases considered
- Serve as a focal point for future consolidation in immunotherapy
[Corixa logo]
THERAPEUTIC AREAS
Cancer
- Bexxar
- Melacine
- Defined-antigen tumor vaccines
Autoimmune Disease
- PVAC treatment for psoriasis
- Anergix.RA/MS
- Anti IFN Receptor monoclonal antibody
Infectious Disease
- MPL in multiple infectious disease vaccines (hepatitis, herpes)
- Tb vaccine
- Chlamydia vaccine
[Corixa logo]
MAJOR PARTNERS
SmithKline Beecham
Schering Plough
Wyeth-Lederle Vaccines
Merck & Company
Organon/Akzo
Japan Tobacco
Zenyaku Kogyo
Zambon Group spa
Biomira
Allergy Therapeutics
2
<PAGE> 3
Rhein Biotech
QLT PhotoTherapeutics
Abgenix
Medarex
Medicis
[Corixa logo]
TECHNOLOGY PLATFORMS
Novel and Disease Specific Antigens
Autoimmune Disease Vaccines -- AnergiX, AnervaX
Ab Therapeutics
Targeted Oncologics -- linkage of radiolabel or ultra potent cytotoxics to
abs or peptides
Novel Adjuvants
[Corixa logo]
ANTIGEN DISCOVERY "ENGINE"
[graphic depicting "engine" process and with following language]
Normal Tissue, Diseased Tissue, cDNA and Protein
[arrow pointing to following words]
Gene Expression Profiling- Quantitative PCR- Full Length
Cloning- Immunohistochemistry- Immunogenicity/Antigenicity In Vitro/In Vivo
[arrow pointing down to following words]
Novel and Disease-specific Antigens
[arrow pointing across to following words]
Vaccines
Antibodies naked, radiolabeled, or coupled with cytoxic drugs
Diagnostics
[Corixa logo]
PRODUCT DEVELOPMENT TECHNOLOGIES
Antibodies -- cancer, autoimmune, infectious disease
Targeted Oncologics -- cancer
Vaccines -- cancer, autoimmune, infectious disease
[Corixa logo]
ANTIBODY EXPERTISE
- Extensive antigen collection
- Generation either internally or with Corixa partners
- Immgenics
- Kirin
- Dyax
- Medarex, Abgenix (auction)
- Purdue Pharma (synthebody)
- Product development - linkage technology
- Radionuclide and ultra potent cytotoxics
[Corixa logo]
VACCINE EXPERTISE
3
<PAGE> 4
- Extensive antigen collection
- Antigen delivery
- Microspheres for both Ab and CTL response
- Protein, DNA or peptide format
- Adjuvants
- MPL, ENHANZYN
- Synthetics from Ribi AGP file
[Corixa logo]
TARGETED ONCOLOGICS
- Radionuclide or cytotoxic drug conjugated antibodies
- ultrapotent cytotoxics
- new class of chemotherapeutics
- 1000 fold more potent than standard chemotherapy
- Tumor activated pro-drugs
- Peptide delivery of doxorubicin (CP1-0004)
- Better anti-tumor activity, overcomes chemotherapy resistance
[Corixa logo]
POWERED BY CORIXA(TM) Ex Vivo Adjuvants Diagnostics
[Corixa logo]
PRODUCT PIPELINE PHASE III
Bexxar(TM) Radiolabeled Antibody SmithKline Beecham
Melacine(R) melanoma vaccine Schering Plough
MPL(R) vaccine adjuvant[vaccination to prevent infectious diseases]
SmithKline Beecham
MPL(R) vaccine adjuvant [vaccination for treatment of allergies] Allergy
Therapeutics, LTD.
ENHANZYN(TM) adjuvant [vaccination for treatment of cancer] Biomira, Inc.
[Theratope]
[Corixa logo]
PRODUCT PIPELINE PHASE II
AnervaX.RA(TM) peptide vaccine [treatment of arthritis]
PVAC(TM) [treatment of psoriasis] Medicis (US, CA) Zenyaku Kogyo(JPN)
AnergiX.RA(TM) complex [treatment of arthritis] N.V. Organon
AnergiX.MS(TM) complex [treatment of multiple sclerosis]
Bexxar(TM) + chemotherapy [treatment of cancer] SmithKline Beecham
Bexxar(TM) [treatment of CLL] SmithKline Beecham
[Corixa logo]
PRODUCT PIPELINE PHASE I
Microsphere delivery and LeIF [use in vaccination for treatment of cancer]
Zambon, SB, Japan Tobacco
Her-2/neu vaccine [treatment of breast and ovarian cancer] SmithKline Beecham
Muc-1 peptide vaccine [treatment of pancreatic cancer]
Leishmania vaccine Gates Foundation
Adjuvants [photodynamic therapy] QLT
[Corixa logo]
4
<PAGE> 5
PRODUCT PIPELINE SELECTED PRE-CLINICAL PROGRAMS
WT-1 vaccine [treatment of leukemia]
MAb [treatment of candidiasis]
Tuberculosis vaccine SmithKline Beecham
Ribi.529 vaccine adjuvant Rhein Biotech
Anti-IFNAR [treatment of autoimmune disease]
[Corixa logo]
BEXXAR(TM)
Antibody Targeted
Micro-Radiation Therapeutic
[Corixa logo]
BEXXAR
- Provides Dual Mechanism of Action
- Antibody triggers apoptosis and recruits human immune system
- Microradiation of tumor 131Iodine
- Permits Patient-Specific Dosing
- Higher efficacy and better safety
- Eliminates Residual Disease
- Higher complete response rates
[Corixa logo]
SELECTIVE TUMOR TARGETING
Bexxar Precision
[Graph depicting dose of energy compared to tissue tolerance and absorbed dose
from Bexxar in certain organs -- points are as follows:
Bone Marrow -- absorbed dose from Bexxar -- approximately 100 dose of energy
Bone Marrow -- tissue tolerance -- approximately 700 dose of energy
Lungs -- absorbed from Bexxar -- approximately 300 dose of energy
Lungs -- tissue tolerance -- approximately 2,500 dose of energy
Bladder -- absorbed dose from Bexxar -- approximately 250 dose of energy
Bladder -- tissue tolerance -- approximately 6,000 dose of energy
Liver -- absorbed from Bexxar -- approximately 350 dose of energy
Liver -- tissue tolerance -- approximately 3,700 dose of energy
Kidneys -- absorbed from Bexxar -- approximately 900 dose of energy
Kidneys -- tissue tolerance -- approximately 3,000 dose of energy
Tumor -- absorbed dose from Bexxar -- approximately 2,500 dose of energy
[Corixa logo]
BEXXAR'S BROAD POTENTIAL B-CALL MALIGNANCIES
[Graph depicting number of U.S. patients compared to CLL, high-grade
malignancies, intermediate malignancies, transformed malignancies and low-grade
malignancies as follows:
5
<PAGE> 6
Low-grade malignancies -- approximately 100,000 patients
Low-grade transformed malignancies -- approximately 130,000 patients
All NHL: Low-grade malignancies -- approximately 100,000 patients, transformed
malignancies -- approximately 120,000 patients, intermediate malignancies --
approximately 230,000 patients, high-grade malignancies -- approximately 280,000
patients
All B-cell: Low-grade malignancies -- approximately 100,000 patients,
transformed malignancies -- approximately 120,000 patients, intermediate
malignancies -- approximately 230,000 patients, high-grade malignancies --
approximately 260,000 patients, CLL malignancies -- approximately 320,000
patients
[Corixa logo]
PIVOTAL PHASE III TRIAL RESULTS
- Data from 60-patient Trial
- Refractory to Chemotherapy
- Prior response less than 6 months
- Clinical Endpoint: Duration of Response
- Compare Bexxar(TM) to prior chemotherapy
- Response Confirmed by Independent Panel
[Corixa logo]
PIVOTAL PHASE III TRIAL RESULTS
Superior to Chemotherapy
<TABLE>
<CAPTION>
Chemotherapy Bexxar(TM) Prior
<S> <C> <C> <C>
Longer Duration of 78% vs. 22%
Response* (p value
less than 0.001)
Overall Response 65% vs. 28%
Rate (p value less
than 0.001)
Complete Response 17% vs. 3%
Rate (p value less
than 0.01)
</TABLE>
* Non-equivalent cases
[Corixa logo]
FIRST-LINE THERAPY TRIAL
- First Stand-alone, First-line Trial of Mab as Treatment for Cancer
- Newly Diagnosed Low-grade NHL
- Enrollment Complete with 76 Patients
- Data Presented in May 2000
- 76% complete response
- 21% partial response
- 3% no response
[Corixa logo]
COMBINATION FIRST-LINE THERAPY
Bexxar Makes the Difference
6
<PAGE> 7
Fludarabine Response [arrow to] Combined Response After Bexxar
[Two pie charts -- First pie chart (Fludarabine Response) shows: CR 2 (14%),
NR (7%), PR 11 (79%); Second pie chart (Combined Response After Bexxar) shows:
CR 10 (71%), PR 4 (29%)]
Fourteen patients treated. Three have progressed. 1 developed HAMA. ASH
1999
[Corixa logo]
<TABLE>
<CAPTION>
BEXXAR EXPANSION TRIALS
<S> <C>
Phase II First-line Fully enrolled
Phases II Fludarabine + Bexxar(TM): 1st-line LG Fully enrolled
Phase II Rituximab Failure Fully enrolled
Phase II Unlabeled vs. Labeled Fully enrolled
Phase II: CHOP + Bexxar(TM): 1st-line LG Fully enrolled
Phase I less than 25% Bone Marrow Involvement Ongoing
Phase I CLL Ongoing
Phase II 1st/2nd Relapse (UK) Ongoing
</TABLE>
[Corixa logo]
BEXXAR INTELLECTUAL PROPERTY
- Composition-of-matter
- Method-of-use
- Formulation
- Manufacturing
- Technical know-how
- Trade secrets
[Corixa logo]
BEXXAR REGULATORY PROCESS
- BLA Submission September 15, 2000 [checkmark]
- Priority review confirmed [checkmark]
- BLA Acceptance Q4'00
- Panel Review Q1 '01
- Approval Q2 '01
[Corixa logo]
PREPARING FOR BEXXAR COMMERCIALIZATION
- Finishing deployment of U.S. Sales Force
- Optimizing Distribution Channels
- Developing Reimbursement Programs
- Radiolabeling at Commercial Scale
- Finalizing Expanded Packaging Facility
- Preparing Site and Sales Representative Training Programs
[Corixa logo]
7
<PAGE> 8
MELACINE(R)
Therapeutic Vaccine for Melanoma Partnered with Schering Plough
[Corixa logo]
MELACINE ALLOGENIC MELANOMA VACCINE
Adjuvant -- ENHANZYN(TM) 250ug CWS +25 ug MPL [arrow to] Melacine
Melanoma Antigen -- Melanoma Lysate 20x10(6) tumor cell equivalents [arrow to]
Melacine
gp100
GD3
Melan A/MART 1
MAGE Antigens
Tyrosinase
HMW -- MAA
[Corixa logo]
MELACINE CLINICAL SUMMARY
- Phase I: One study, 48 patients
- Stage 3 & 4 melanoma
- Phase II: Seven studies, 128 patients
- Stage 3 & 4 melanoma with measurable tumor
- Integrated results -- 9% CR + PR
- Median survival 33.7 months for responders
- Phase III: Three studies, 1082 patients
- Melacine vs. chemotherapy (stage 4)
- Melacine + Intron A vs. Intron A (stage 4)
- Melacine vs. observation (stage 2)
[Corixa logo]
MELACINE ADJUNCTIVE THERAPY, STAGE 2 MELANOMA
Phase III Trial (Southwest Oncology Group Study 9035)
Stage 2 Melanoma Surgical Removal
Melacine (40 doses over 2 years) 346 patients
Observation-Control -- 343 patients
Evaluate for Disease Recurrence
[Corixa logo]
8
<PAGE> 9
MELACINE PIVOTAL TRIAL RESULTS
- Stage II disease
- Improved disease free survival post surgery (p=.04)
- Greater benefit in patients with smaller (<3mm) thick tumors (p=.018)
- Stage IV disease
- Melacine + Intron A therapy resulted in greater survival in women than
did treatment with Intron A (p=.018)
[Corixa logo]
MELACINE BLA FILING
- Centered on Stage II disease
- Prolongation of disease free survival
- Comprehensive tabulation of all studies
- Data sweep through December 2000
- Anticipated filing Q2:2001
[Corixa logo]
PVAC(TM)
Potential Treatment for Moderate to Severe Plaque Psoriasis
9
<PAGE> 10
CLINICAL DEVELOPMENT TIMELINE
- Initiated Phase II US trial end of Jan 2000
- Additional recommendations by FDA to increase sample size and modify
statistical plan
- Sample size was increased from 132 to 240 patients (now 60
patients/group)
- More detailed statistical analysis plan with one primary efficacy
objective
- Accrual for US Phase II completed (N=240) in August 2000
[Corixa logo]
CLINICAL DEVELOPMENT TIMELINE
- Per protocol, trial can not be unblinded until all date queries are resolved
and the data base is locked (December 2000)
- Preliminary data from US Phase II trial to FDA by Q1, 2001 to discuss Phase
III plans
- Site of PVAC fermentation changed to Montana facility in Q4, 2000 - Q1, 2001
[Corixa logo]
POTENTIAL PVAC ADVANTAGES
- Ease of administration -- 2 injections
- Durability of response post administration
- Side effects limited to minor (7x10mm) injection site reaction
- Rapidity of response -- many patients show significant reduction in PASI in
six weeks or less
- Less expensive to produce than MAbs
[Corixa logo]
PVAC PARTNERS
- Zenyaku Kogyo -- Japan
- Medicis -- USA, Canada
- Other Territories under discussion include Europe, Asia (excluding Japan)
+/-ROW
[Corixa logo]
MPL(R) -- VACCINE ADJUVANT
- Tested in thousands of patients
- Enhances Th1 driven antibody response
- Multiple Phase III trials ongoing or completed
- Hepatitis B (efficacy established)
- Herpes Virus (efficacy in women established)
- Subject of multiple partnerships
[Corixa logo]
HEPATITIS B VACCINE
% of Subjects with Protective Ab Levels
10
<PAGE> 11
[Graph depicting percentage of subjects with protective Ab levels. Vertical goes
from 0 to 100 and measures percentage; Horizontal goes from 0 to 7 and measures
dose regimen in months. Energix and Energix + MPL 1st dose is at points 0% and 0
months, 25% at approximately 10 days, 80% at approximately 25 days, 75% at
approximately 1 month, 100% at approximately 35 days, at which point it levels
off. Energix only, 25% at approximately 1 month, 60% at approximately 35 days,
45% at approximately 45 days, 48% at approximately 2 months, 50% at
approximately 3 months, levels until approximately 5.5 months, at which point it
rises to 100% at six months. Energix and Energix + MPL dose regimens given at 0,
1 and 6 months.]
[Corixa logo]
CLINICAL MILESTONES
- Phase I/II AnergiX.RA(TM)
- Ribi.529 adjuvant IND, Argentina
- Bexxar BLA Acceptance
- Bexxar Data at ASH
- MPL(TM)/Energix B(R) EU regulatory filing
- Bexxar Advisory Panel Review
- Phase II PVAC
- Phase III Melacine Data Sweep
- Complete Phase I Her-2/neu vaccine
- Additional tumor and/or infectious disease vaccine IND
[Corixa logo]
PARTNERING TARGETS
- Bexxar -- Ex -- US
- PVAC -- EU
- AnergiX.MS
- WT-1 Leukemia Vaccine
- Ribi.529 synthetic adjuvant
- Ribi.552 cardio-protectant
- Cancer Diagnostics
[Corixa logo]
CORIXA CLINICAL PIPELINE
<TABLE>
<S> <C> <C> <C> <C> <C>
Compound Disease Program Preclinical Clinical Preparing
Indication Development License
Phase I Application
Phase II
Phase III
Bexxar lymphoma Ab [completed] [completed] Filed
Melacine Stage II Vaccine [completed] [completed] Approved in
melanoma Canada, BLA
being prepared
MPL allergy Adjuvant [completed] Marketed on
named patient
</TABLE>
11
<PAGE> 12
<TABLE>
<S> <C> <C> <C> <C>
basis in
Europe
MPL Hepatitis B Adjuvant [completed] [completed]
vaccine
MPL Herpes virus Adjuvant [completed] [completed]
vaccine
ENHANZYN Theratope Adjuvant [completed] [completed]
PVAC(TM) psoriasis Vaccine [completed] [completed
through
Phase II]
AnervaX.RA rheumatoid Vaccine [completed] [completed
arthritis through
Phase II]
AnergiX.RA rheumatoid Vaccine [completed] [completed
arthritis through
Phase II]
AnergiX.MS multiple Vaccine [completed] [completed
sclerosis through
Phase II]
Bexxar+chemo Low+ MAb [completed] [completed
therapy intermediate through
NHL Phase II]
Bexxar CLL MAb [completed] [completed
through
Phase II]
Her2/neu breast/ovarian MAb [completed] [completed
cancer through
Phase I]
Muc-1 pancreatic MAb [completed] [completed
cancer through
Phase I]
Leishmania leishmania Vaccine [completed] [completed
vaccine through
Phase I]
Microsphere breast cancer Delivery [completed] [completed
delivery through
Phase I]
ENHANZYN/MPL Photodynamic Adjuvant [completed] [completed
therapy through
Phase I]
</TABLE>
CORIXA PRECLINICAL PIPELINE
<TABLE>
<CAPTION>
Potential Product Disease Indication Type
<S> <C> <C>
Prostate Cancer Vaccine Prostate Cancer Vaccine
Breast Cancer Vaccine Breast Cancer Vaccine
Colon Cancer Vaccine Colon Cancer Vaccine
Lung Cancer Vaccine Lung Cancer Vaccine
Ovarian Cancer Vaccine Ovarian Cancer Vaccine
Mammaglobin Vaccine Breast Cancer Vaccine
WT-1 Vaccine Leukemia, Myelodysplasia Vaccine
CPI-0005 Solid tumors TAP
UTAP Cancer TAP
Antibody-TST Chemo labeled Cancer Mab
Antibody-TST Radio-labeled Cancer Mab
</TABLE>
CORIXA PRECLINICAL PIPELINE
<TABLE>
<CAPTION>
Potential Product Disease Indication Type
<S> <C> <C>
Growth Factor Antagonist Solid Tumors TST
Duocarmycian B2 Cancer TAP
IFNAR-1 Autoimmunity Transplantation Mab
Chlamydia Vaccine Sexually Transmitted Vaccine
Disease
Anti-Phosphomannan Candidiasis Mab
Tuberculosis Vaccine Tuberculosis Vaccine
RC-552 Ischemic Reperfusion AGP
Injury
Leukemia Vaccine Leukemia Vaccine
Lymphoma Vaccine Lymphoma Vaccine
Pancreatic Cancer Vaccine Pancreatic Cancer Vaccine
Anti-CXCR3 Receptor Mab Inflammatory Disease Mab
</TABLE>
INVESTMENT HIGHLIGHTS
- Combination of two leading biotechnology companies to create immunotherapy
leader
- Technology and product rich
- Industrialized antigen discovery machine
12
<PAGE> 13
- Antibody therapeutics
- Targeted oncologics
- "Powered by Corixa" approach to component technologies
- Diverse pipeline, with multiple late stage product opportunities
- Strong partners - targeted sales force
[Corixa logo]
ADDITIONAL INFORMATION AND WHERE TO FIND IT
Corixa plans to file a Registration Statement on SEC Form S-4 in connection
with the merger, and Corixa and Coulter expect to mail a Joint Proxy
Statement/Prospectus to stockholders of Corixa and Coulter containing
information about the merger. Investors and security holders are urged to read
the Registration Statement and the Joint Proxy Statement/Prospectus carefully
when they are available. The Registration Statement and the Joint Proxy
Statement/Prospectus will contain important information about Corixa, Coulter,
the merger and related matters. Investors and security holders will be able to
obtain free copies of these documents through the website maintained by the
U.S. Securities and Exchange Commission at http://www.sec.gov. Free copies of
the Joint Proxy Statement/Prospectus and these other documents may also be
obtained:
- from Corixa by completing the material request form located in
the "request materials" section of Corixa's website at
http://www.corixa.com/financials/index.htm or by mail to Corixa, 1124 Columbia
Street, Suite 200, Seattle, Washington 98104-2040, attention: Investor
Relations, telephone: (206)754-5711; or
- from Coulter by directing a request through the Investors
Relations portion of Coulter's website at http://www.coulterpharm.com or by mail
to Coulter, 600 Gateway Boulevard, South San Francisco, California 94080,
attention: Investor Relations, telephone: (650)553-1190.
In addition to the Registration Statement and the Joint Proxy Statement/
Prospectus, Corixa and Coulter file annual, quarterly and special reports,
proxy statements and other information with the Securities and Exchange
Commission. You may read and copy any reports, statements or other information
filed by Corixa or Coulter at the SEC public reference rooms at 450 Fifth
Street, N.W., Washington, D.C. 20549 or at any of the Commission's other public
reference rooms in New York, New York and Chicago, Illinois. Please call the
Commission at 1-800-SEC-0330 for further information on the public reference
rooms. Corixa's and Coulter's filings with the Commission are also available to
the public from commercial document-retrieval services and at the website
maintained by the Commission at http://www.sec.gov.
Interests of Certain Persons in the Merger.
Coulter will be, and certain of Coulter's directors and executive officers may
be, soliciting proxies from Coulter stockholders in favor of the adoption of
the merger agreement. In addition, Corixa will be, and certain of Corixa's
directors and executive officers may be, soliciting proxies from Corixa
stockholders in favor of the adoption of the merger agreement. The directors
and executive officers of Coulter and the directors and executive officers of
Corixa may be deemed to be participants in Coulter's and Corixa's solicitation
of proxies.
The directors and executive officers of Coulter have interests in the merger,
some of which may differ from, or may be in addition to, those of Coulter's
stockholders generally. For a description of such interests and a list of each
company's directors and executive officers, please see the press release filed
with the SEC pursuant to Rule 425 by Corixa and Coulter on October 16, 2000.
[Corixa logo]
[Corixa Logo] The Immunotherapy Powerhouse
13
